FDA 483 - S.M.A.I.O - September 19, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of S.M.A.I.O in Saint-Priest identified significant deficiencies in the firm's design and development activities for its medical device software. The company's software development procedure and product requirements document contained ambiguous, incomplete, or non-measurable design inputs, and a distributed Class II medical device software, "KEOPS Balance Analyzer 3D, version 2.2", was found to lack a completed risk analysis. These issues indicate a failure to adequately establish design plans, potentially impacting the safety and effectiveness of the device.
ID · 29da26e5-adc0-46d6-b94a-186d341599dc